Targets › GDNF
3 programs from 3 companies in 5 trials: 4 Phase 1, 1 Phase 2; Neurology, Ophthalmology; next expected readout Jun 2027.
Neurotrophic factor that enhances survival and morphological differentiation of dopaminergic neurons and increases their high-affinity dopamine uptake. Acts by binding to its coreceptor, GFRA1, leading to autophosphorylation and activation of the RET receptor. (UniProt, P39905)
Open in Phaseline: the race on GDNF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AskBio | AAV2-GDNF Adeno-associated virus serotype 2 delivering glial cell line-derived neurotrophic factor ( | GDNF | Phase 2 | Parkinson Disease | Aug 2028 |
| Brain Neurotherapy Bio | AAV2-GDNF AAV2-delivered GDNF gene therapy | GDNF | Phase 1 | Parkinson's Disease; Multiple System Atrophy | Jun 2027 |
| Cedars-Sinai Medical Center | CNS10-NPC-GDNF Neural progenitor cells engineered to produce glial cell line-derived neurotrophic factor | GDNF | Phase 1 | Retinitis Pigmentosa; Amyotrophic Lateral Sclerosis | – |
Parkinson's Disease (1) Multiple System Atrophy (1) Retinitis Pigmentosa (1) Amyotrophic Lateral Sclerosis (1) Parkinson Disease (1)
other (2), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.